tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

ImmunoGen sees FY23 revenue excluding Elahere sales $45M-$50M

The company continues to expect that its existing cash and cash equivalents, together with anticipated future product and collaboration revenues, will fund operations for more than two years.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on IMGN:

Disclaimer & DisclosureReport an Issue

1